

Antivirals for treatment of non-severe influenza: a systematic review and network meta-analysis of randomized controlled trials

Ya Gao^{1,2}, PhD, Yunli Zhao^{3,4}, MD, Ming Liu^{1,2}, PhD, Shuyue Luo^{5,6}, MD, Yamin Chen^{7,8}, PhD, Xiaoyan Chen⁹, MD, Qingyong Zheng¹, MD Jianguo Xu¹, MD, Yanjiao Shen^{10,2}, MD Wanyu Zhao^{5,6}, MD, Zhifan Li¹¹, MD, Sha Huang⁹, MD, Jie Huang⁹, MD, Professor Jinhui Tian¹, PhD, Professor Gordon Guyatt^{2,12}, MD, Qiukui Hao^{13,2}, MD

1. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

2. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

3. Department of Geriatric Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

4. Chongqing Municipality Clinical Research Center for Geriatrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

5. National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China

6. Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China

7. Clinical Nursing Teaching and Research Section, The Second Xiangya Hospital, Central South University, Changsha, China

8. Xiangya School of Nursing, Central South University, Changsha, China

9. Department of Geriatric, Zigong Affiliated Hospital of Southwest Medical

University, Zigong, China

10. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan

University, Chengdu, Sichuan, China

11. The First Clinical Medical College of Lanzhou University, Lanzhou, China

12. Department of Medicine, McMaster University, Hamilton, ON, Canada

13. School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada

Corresponding to: Dr Qiukui Hao, School of Rehabilitation Science, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence, and Impact; McMaster University; Hamilton, ON, Canada; Email: haoqiukui@gmail.com. Phone number: +1-365-324-6281.

Word count for text: 3651

Number of references: 45

Number of tables: 2

Number of figures: 3

Summary

Background: The optimal antiviral drug for treatment of non-severe influenza remains unclear. To support an update of WHO guidelines on antiviral treatment for influenza, this systematic review compared effects of antiviral drugs for treating non-severe influenza.

Methods: We systematically searched Medline, Embase, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, Global Health, Epistemonikos, and ClinicalTrials.gov for randomized controlled trials published between database inception and 20 September 2023, comparing direct-acting influenza antiviral drugs, including but not limited to baloxavir, favipiravir, laninamivir, oseltamivir, peramivir, umifenovir, and zanamivir, to placebo, standard care, or another antiviral drug for treating people with non-severe influenza. We performed frequentist network meta-analyses to summarize the evidence and evaluated the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. We registered the protocol with PROSPERO, CRD42023456650.

Findings: We identified 11878 records, of which 73 trials with 34332 participants proved eligible. Compared with standard care or placebo, all antiviral drugs have little or no effect on mortality for low-risk patients (risk difference (RD) varied from 0.12 fewer to 0.02 fewer per 1000) and high-risk patients (RD varied from 1.22 fewer to 0.24 fewer per 1000) (all high certainty). All antivirals (no data for peramivir and amantadine) have little or no effect on admission to hospital (RD varied from 2 fewer

to 1 more per 1000) for low-risk patients (high certainty). With respect to hospital admission, for high-risk patients, oseltamivir (RD 4 fewer per 1000, 95% CI 10 fewer to 4 more; high certainty) and zanamivir (RD 4 more per 1000, 95% CI 4 fewer to 15 more; high certainty) have little or no effect; baloxavir may reduce risk (RD 16 fewer per 1000, 95% CI 20 fewer to 4 more; low certainty); all other drugs may have little or uncertain effect. For time to alleviation of symptoms, baloxavir probably reduces symptom duration (mean difference (MD) 1.02 days lower, 95% CI 1.41 lower to 0.63 lower; moderate certainty); umifenovir may reduce symptom duration (MD 1.10 days lower, 95% CI 1.57 lower to 0.63 lower; low certainty); oseltamivir probably has no important effect (MD 0.75 days lower, 95% CI 0.93 lower to 0.57 lower, moderate certainty) and other drugs may have no important or little effect. For adverse events related to treatment, baloxavir (RD 32 fewer per 1000, 95% CI 52 fewer to 6 fewer; high certainty) has few or no such events; oseltamivir (RD 28 more per 1000, 95% CI 12 more to 48 more; moderate certainty) probably increases such events; other drugs may have little or no effect, or uncertain effect.

Interpretation: Baloxavir may reduce the risk of hospital admission for high-risk patients and probably reduces time to alleviation of symptoms, without increasing adverse events related to treatment in patients with non-severe influenza. All other antivirals either probably have little or no effect, or uncertain effects on patient-important outcomes.

Funding: WHO.

Keywords: Non-severe influenza; Antiviral treatment; Efficacy; Safety; Network meta-

analysis

Research in context

Evidence before this study

Antiviral drugs may play a role in reducing illness duration, preventing serious complications, and lowering morbidity, particularly in high-risk populations. Previous systematic reviews and network meta-analyses have assessed the effects of antiviral drugs for treating influenza, but none assessed all approved antivirals for influenza or addressed patient-important outcomes of mortality and admission to hospital. The effect of many antiviral drugs for treating patients with non-severe influenza remains uncertain.

Added value of this study

This systematic review and network meta-analysis represents the most comprehensive assessment of the benefits and harms of antivirals in treating patients with non-severe influenza and demonstrates that baloxavir may reduce the risk of admission to hospital for high-risk patients and probably reduces time to alleviation of symptoms, does not increase adverse events related to treatment, but may increase emergence of resistance. Oseltamivir has little or no effect on mortality and admission to hospital, probably has no important effect on time to alleviation of symptoms, and probably increases adverse events related to treatments. Other antivirals probably have little or no effect on mortality and admission to hospital and may have no important effect on time to alleviation of symptoms.

Implications of all the available evidence

Our study provides evidence that baloxavir may be superior to standard care or

placebo in reducing the risk of admission to hospital for high-risk patients and probably decreases time to alleviation of symptoms with few or no adverse effects. These findings support the use of baloxavir for treatment of high-risk non-severe influenza patients.

Introduction

Influenza, a viral respiratory disease caused by influenza virus, affects people worldwide.¹ Although most people with influenza have upper respiratory symptoms that are self-limited and recover within a week without medical attention, some individuals experience severe or fatal complications.^{2,3} This number is substantial: each year, influenza is estimated to cause 3 to 5 million cases of severe illness and 290,000 to 650,000 respiratory deaths worldwide.^{3,4}

Antiviral drugs such as neuraminidase inhibitors (e.g., oseltamivir, zanamivir, laninamivir, and peramivir) and selective cap-dependent endonuclease inhibitors (e.g., baloxavir) may play a role in reducing illness duration, preventing serious complications, and lowering morbidity and mortality, particularly in high-risk populations.^{5,6} In 2022, the World Health Organization (WHO) published guidelines for clinical management of severe illness caused by influenza virus infections. These guidelines conditionally recommended the use of oseltamivir but advised against using inhaled zanamivir, inhaled laninamivir, or intravenous peramivir for individuals suspected or confirmed to have influenza virus infection with or at risk of severe illness.⁷ Most of the evidence supporting these recommendations was, however, of low or very low certainty, leaving optimal management in doubt.

Previous systematic reviews and network meta-analyses have assessed the effects of antiviral drugs for treating influenza⁸⁻¹⁰, but have been limited in failure to provide absolute effects of interventions,⁸⁻¹⁰ in their focus solely on specific categories of interventions such as neuraminidase inhibitors or particular subtypes

of influenza such as seasonal influenza,⁸⁻¹⁰ or overlooked crucial patient-important outcomes including mortality and hospitalization.⁸⁻¹⁰ Additionally, some studies^{9,10} do not assess the certainty of the evidence and none include recent trials.¹¹⁻¹⁴

To evaluate the effectiveness and safety of antiviral treatment for patients with non-severe influenza and thus support an update of WHO guidelines on antiviral treatment for influenza,⁷ we performed a systematic review and network meta-analysis of randomized controlled trials (RCTs).

Methods

Registration and reporting

We registered this systematic review protocol with PROSPERO (CRD42023456650) and reported the review according to the guideline of Preferred Reported Items for Systematic Reviews and Meta-Analyses (PRISMA) for network meta-analyses.¹⁵

Search strategy and selection criteria

With the aid of a medical librarian, we searched Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Global Health, Epistemonikos, ClinicalTrials.gov from databases inception to 20 September 2023 (Appendix 1). To identify additional trials, we manually searched reference lists of relevant previous systematic reviews and eligible studies.

We included RCTs that compared direct-acting influenza antiviral drugs to placebo, standard care, or another antiviral drug for people with suspected or

laboratory-confirmed (by RT-PCR assay, rapid antigen test, or immunofluorescence assay) non-severe influenza. We used the WHO definitions for disease severity; severe illness from influenza infection was defined as an illness that requires hospitalisation.⁷ We defined non-severe influenza as the absence of any criteria for severe influenza and included RCTs enrolling naturally infected patients with any etiology of influenza virus, including seasonal influenza viruses, pandemic influenza viruses, and zoonotic influenza viruses.

We focused on influenza antiviral drugs approved by the US Food and Drug Administration (FDA) or approved for use in different parts of the world.⁵ Eligible antiviral drugs included baloxavir, oseltamivir, laninamivir, zanamivir, peramivir, umifenovir, favipiravir, amantadine, and rimantadine.

We did not impose any restrictions on publication language, patient age, or dose and administration route of antiviral drugs. Eligible trials reported at least one of the outcomes of interest. We excluded studies investigating the antiviral effects of Traditional Chinese medicines and antiviral drugs combined with adjunctive therapies as well as trials that used antivirals as prophylaxis against influenza in individuals who had been exposed to influenza virus.

Using Covidence (<https://covidence.org/>), pairs of reviewers independently screened titles and abstracts of all records and full texts of potentially eligible records. We checked the retractions for all eligible publications, if the study was retracted from the publication, we excluded the study from our review.¹⁶ Pairs of reviewers independently extracted data on study characteristics, patient

characteristics, characteristics of interventions, and outcomes (Appendix 2). Reviewers resolved discrepancies by discussion or, if necessary, with the assistance of a third party for adjudication.

Data analysis

Patient-important outcomes of interest to the guideline panel included mortality, admission to hospital, admission to intensive care unit (ICU), progression to mechanical ventilation, duration of mechanical ventilation, duration of hospitalization, time to alleviation of symptoms, hospital discharge destination, emergence of resistance, any adverse events, adverse events related to treatments, and serious adverse events. We defined time to alleviation of symptoms as time from the start of treatment to the alleviation of all influenza-associated symptoms.^{17,18}

We conducted pairwise meta-analyses for all direct comparisons of each outcome using the Hartung-Knapp-Sidik-Jonkman (HKSJ) random-effects model in R version 4.2.1 (R Foundation for Statistical Computing). To assess the between-study heterogeneity, we visually inspected forest plots and used the I^2 statistic. For comparisons that included at least 10 studies, to assess publication bias, we used Harbord's test for dichotomous outcomes and Egger's test for continuous outcomes,^{19,20} as well as a visual assessment of the funnel plot.

For emergence of resistance, because no such events occur in standard care or placebo groups, to estimate pooled emergence of resistance rates for each antiviral, we conducted meta-analyses of the proportion of actively treated patients in whom resistance occurred using the Hartung-Knapp-Sidik-Jonkman (HKSJ) random effects

model with the restricted maximum likelihood (REML) heterogeneity estimator method.^{21,22} To stabilize variances, we applied the Freeman-Tukey double arcsine transformation.²³

We drew network plots for each outcome using STATA 15.0 (StataCorp, College Station, Texas, USA). Using netmeta package in R version 4.2.1 (R Foundation for Statistical Computing), we performed frequentist random-effects network meta-analyses with a graph-theoretical approach.²⁴ The estimator was based on weighted least-square regression using the Moore-Penrose pseudoinverse method.²⁴ For each outcome, we used the “design-by-treatment” model (global test) to assess the coherence assumption for the entire network.²⁵ We calculated indirect estimates from the network by node-splitting and a back-calculation method.²⁶ To evaluate local (loop-specific) incoherence in each closed loop of the network - the difference between direct and indirect evidence - we used the node-splitting method and calculated a P-value for the test of incoherence.²⁷

We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for mortality, admission to hospital, any adverse events, and adverse events related to treatments. For mortality and hospital admission, we applied the continuity correction of 0.5 for trials with 0 events.²⁸ We calculated absolute effects using the network RR estimates and the baseline risk estimates. To estimate absolute effects of antivirals on mortality and hospital admission, the guideline panel recommended use of two baseline risk categories for patients at low risk and high risk for severe complications. We defined high-risk patients using the definitions from the 2022 WHO guidelines.⁷

For mortality, we obtained baseline risks for low-risk (0.2 per 1000) and high-risk (2 per 1000) patients from observational studies.^{29,30} For other outcomes for which reliable observational data were not available, we used the median baseline risk in the standard care or placebo group of eligible RCTs.

For ICU admission and serious adverse events, the median event rate from the standard care or placebo arm was less than 1%, we directly calculated the absolute risk differences (RDs) with 95% CIs. We calculated mean differences (MDs) with 95% CIs for continuous outcomes. When standard deviations (SDs) were missing, we estimated them using the methods described in the Cochrane Handbook.³¹

If at least two trials provided relevant information for each subgroup, we performed the following prespecified within-trial subgroup analyses: seasonal versus zoonotic versus pandemic influenza viruses; confirmed versus suspected influenza virus infection; children < 2 years, children versus adults and adolescents versus elderly (≥ 65 years); patients at increased risk of severe complications versus at low risk (Appendix 2 presents further details). We planned to assess the credibility of the subgroup hypothesis using the Instrument for assessing the Credibility of Effect Modification Analyses (ICEMAN) tool.³² Pairs of reviewers independently evaluated the risk of bias of eligible RCTs using a modified Cochrane risk of bias tool (Appendix 2).³³

To assess the certainty of evidence for each outcome, we used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for network meta-analysis.^{34,35} We evaluated the risk of bias, imprecision, inconsistency,

indirectness, and publication bias, and rated the certainty of evidence for direct estimates as high, moderate, low, or very low.³⁶ We assessed imprecision at the network level using the minimally important difference (MID) as a threshold.³⁷ The guideline panel specified an MID as 0.3% for mortality, 1.5% for admission to hospital, 1% for admission to ICU, 1% for any adverse events and adverse events related to treatments, 0.5% for serious adverse events, 5% for emergence of resistance, and 1 day for time to alleviation of symptoms and duration of hospitalization. We rated imprecision following GRADE guidance (Appendix 2 presents further details).^{38,39} We developed the summary of findings tables for comparisons of each antiviral versus standard care or placebo in MAGICapp following GRADE guidance.^{40,41}

Role of the funding source

The funder had no role in study design, data collection, analysis, and interpretation, or writing of the manuscript and the decision to submit.

Results

The electronic search identified 11878 records. After screening 8944 unique titles and abstracts and 459 full texts, 87 articles reporting 73 unique RCTs proved eligible (Figure 1). Appendix 3 lists the eligible trials.

Eligible trials were published from 1971 through 2023 and evaluated eight unique antivirals: baloxavir, favipiravir, laninamivir, oseltamivir, peramivir, umifenovir, zanamivir, and amantadine, with the most common comparison being between oseltamivir and standard care or placebo (Appendix 4). Sample sizes ranged

from 14 to 3266 (a total of 34332); the median of mean age was 35.0 years, and the median proportion of men was 49.8%. The follow-up for outcomes ranged from 5 to 29 days.

Appendix 5 presents the risk of bias of eligible trials for each outcome. Nine trials were at low or probably low risk of bias for all reported outcomes. The main limitations were inadequate allocation concealment and the lack of blinding of data collectors, outcome assessors, and data analysts.

Figure 2 and Appendix 6 present network plots for each outcome. We did not find substantial between-study heterogeneity for most outcomes and most comparisons (Appendix 7). Tests of incoherence raised no concerns of global incoherence (Appendix 8) for all outcomes and no concerns of local incoherence (Appendix 9) between direct and indirect evidence except for time to alleviation of symptoms. Appendix 10 presents network relative estimates and absolute estimates for each comparison for outcomes, with certainty of evidence. Table 1, Table 2, and Appendix 11 present the GRADE summary of findings for antivirals versus standard care or placebo. We did not find evidence of intransitivity. We found no evidence of publication bias (Appendix 12).

Forty-one trials including 23892 patients reported mortality. High certainty evidence showed that, compared with standard care or placebo, seven antivirals (i.e. baloxavir, favipiravir, laninamivir, oseltamivir, peramivir, umifenovir, zanamivir) have little or no effect on mortality in low-risk (RD varied from 0.12 fewer to 0.02 fewer per 1000) or high-risk (RD varied from 1.22 fewer to 0.24 fewer per 1000) patients

(Figure 3, Table 1, Table 2, and Appendix 11).

Twenty-eight trials involving 17262 patients reported admission to hospital for all antivirals except for peramivir and amantadine (no data available). For low-risk patients, there proved little or no difference between six antivirals (baloxavir, favipiravir, laninamivir, oseltamivir, umifenovir, and zanamivir) and standard care or placebo in admission to hospital (RD varied from 2 fewer to 1 more per 1000; high certainty). For admission to hospital in high-risk patients, compared with standard care or placebo, baloxavir may reduce risk (RD 16 fewer per 1000, 95% CI 20 fewer to 4 more; low certainty); oseltamivir (RD 4 fewer per 1000, 95% CI 10 fewer to 4 more; high certainty) and zanamivir (RD 4 more per 1000, 95% CI 4 fewer to 15 more; high certainty) have little or no effect; and laninamivir may have little or no effect (RD 2 more per 1000, 95% CI 21 fewer to 979 more; low certainty) (Figure 3, Table 1, Table 2, and Appendix 11).

Two trials with 1626 patients provided data on ICU admission for oseltamivir and peramivir. Compared with standard care or placebo, oseltamivir has little or no effect on admission to ICU (RD 2 fewer per 1000, 95% CI 7 fewer to 3 more; high certainty). We are uncertain whether peramivir reduces admission to the ICU (Figure 3). No data is available regarding the effect of other antivirals on ICU admission.

Fifty-nine trials enrolling 24086 patients reported time to alleviation of symptoms. Compared with standard care or placebo, baloxavir probably reduces symptom duration (MD 1.02 days lower, 95% CI 1.41 lower to 0.63 lower; moderate certainty); umifenovir may reduce symptom duration (MD 1.10 days lower, 95% CI

1.57 lower to 0.63 lower; low certainty); while oseltamivir (MD 0.75 days lower, 95% CI 0.93 lower to 0.57 lower, moderate certainty) and zanamivir (MD 0.68 days lower, 95% CI 0.93 lower to 0.43 lower, moderate certainty) probably have no important effect (Figure 3, Table 1, Table 2, and Appendix 11).

Three trials with 234 patients provided data on duration of hospitalization for oseltamivir, peramivir, and zanamivir. The evidence is very uncertain as to whether these drugs reduce duration of hospitalization (Figure 3). No data is available regarding the effect of other antivirals on duration of hospitalization.

Forty-nine trials with 22868 patients reported data on overall adverse events. No data is available for amantadine. Compared with standard care or placebo, baloxavir (RD 52 fewer per 1000, 95% CI 87 fewer to 17 fewer; high certainty) does not increase overall adverse events and zanamivir (RD 28 fewer per 1000, 95% CI 48 fewer to 7 fewer; low certainty) may not result in an increase. It is uncertain whether favipiravir, laninamivir, oseltamivir, peramivir, and umifenovir increase adverse events (Figure 3).

Thirty-six trials with 19298 patients reported data on adverse events related to treatments. Compared with standard care or placebo, baloxavir (RD 32 fewer per 1000, 95% CI 52 fewer to 6 fewer; high certainty) does not increase adverse events related to treatment and oseltamivir (RD 28 more per 1000, 95% CI 12 more to 48 more; moderate certainty) probably increases adverse events related to treatment. Favipiravir, peramivir, and zanamivir may not increase adverse events related to treatment. We are uncertain whether umifenovir increases adverse events related to

treatment (Figure 3).

Fifty-eight trials involving 32043 patients provided low to moderate evidence that there may be little or no difference in serious adverse events between baloxavir, favipiravir, laninamivir, oseltamivir, peramivir, or zanamivir and standard care or placebo. No data is available for umifenovir and amantadine on serious adverse events. (Figure 3, Table 1, Table 2, and Appendix 11).

Twelve trials enrolling 1554 patients reported the emergence of resistance for participants who received antivirals. Baloxavir may have an important impact on emergence of drug resistance (percentage 9.97%, 95% CI 0.02% to 31.79%; low certainty). Zanamivir may have no important impact on emergence of drug resistance (percentage 0%, 95% CI 0% to 11.66%; low certainty). We are uncertain whether oseltamivir and peramivir increase emergence of drug resistance (very low certainty; Appendix 13). There was no evidence regarding drug resistance for other antivirals from included RCTs.

The within-trial subgroup analyses and meta-regression analyses did not reveal any subgroup effects (Appendix 14 and Appendix 15). Our sensitivity analyses using the RD as summary effect measure for mortality and hospital admission (Appendix 16), only including studies with confirmed influenza patients (Appendix 17), and only including studies with patients at high risk (Appendix 18) showed similar results to primary analyses of all patients.

Discussion

In patients with non-severe influenza, we found high certainty evidence that

compared with standard care or placebo, baloxavir, favipiravir, laninamivir, oseltamivir, peramivir, umifenovir, and zanamivir have little or no effect on mortality for low-risk and high-risk patients, high certainty evidence that oseltamivir and zanamivir have little or no effect on admission to hospital for high-risk patients, and low certainty evidence that baloxavir may reduce the risk of admission to hospital for high-risk patients. All antivirals have little or no effect on admission to hospital for low-risk patients. With respect to time to alleviation of symptoms, baloxavir probably reduces symptom duration; oseltamivir and zanamivir probably have no important effect; laninamivir, peramivir, and amantadine may have no important effect; and umifenovir may reduce symptom duration. Baloxavir does not increase adverse events related to treatment but may result in resistance in approximately 10% of those treated. Oseltamivir probably increases adverse events related to treatment. Other antivirals probably or may have little or no effect on adverse events.

The strengths of the review include a comprehensive synthesis of all available evidence on the benefits and harms of antivirals for non-severe influenza patients; independent duplicate study identification, selection, data extraction, and risk of bias assessment; and application of the GRADE approach to rate the certainty of evidence. To facilitate interpretation of the results, we present absolute effects. Based on the WHO guideline development panel's discussion and suggestions, we evaluated the effects of antivirals on mortality and hospital admission for both low-risk and high-risk populations.

The WHO guideline panel provided us with the MID values for patient-

important outcomes and reviewed the results of our review. We used these MID values to interpret the results, assist our imprecision rating, and draw conclusions.

During the rating of imprecision, we followed GRADE guidance and considered external indirect evidence.^{38,39} For certain outcomes, such as mortality in patients at low and high risk, and admission to hospital in low-risk patients, where the baseline risk was lower than the MID, the absolute effects between comparisons did not exceed the MID, and no intervention was superior to the other despite the certainty of evidence. Therefore, we rated the certainty of evidence for all comparisons as high certainty.

Our review has limitations. The evidence for some antiviral drugs and some outcomes was limited. The panel was also interested in progression to mechanical ventilation, duration of mechanical ventilation, and hospital discharge destination, but no trials reported these outcomes. Because within-trial subgroup information was limited, we were only able to conduct within-trial subgroup analysis for certain outcomes and comparisons and did not find any significant subgroup effects. We performed meta-regression analyses for the effect modifiers and also did not find significant subgroup effects.

For mortality and hospital admission, to estimate separately absolute effects for patients at low risk and high risk using network relative estimates and the baseline risks, we calculated risk ratios and applied the continuity correction of 0.5 for trials with 0 events.²⁸ Reassuringly, our findings were robust to sensitivity analyses using RDs as the summary measure.

Due to the high risk of bias or serious imprecision, the certainty of evidence was low for many comparisons. As future trials emerge, we anticipate an improvement in the certainty of evidence and will periodically update this systematic review and network meta-analysis.

Several network meta-analyses have evaluated antivirals for treating influenza^{8-10,42,43}, but none assessed all approved antivirals for influenza and none focused on patient-important outcomes of mortality and admission to hospital. Compared with previous network meta-analyses^{8-10,42,43}, we included more trials and patients, assessed the certainty of evidence using the GRADE approach, and presented absolute effects. Our findings on baloxavir are consistent with previous network meta-analyses that baloxavir probably reduces time to alleviation of symptoms without increasing adverse events.^{8,10}

Previous pairwise meta-analyses, including no more than nine studies, have evaluated the effects of oseltamivir on influenza and reported that, compared to standard care or placebo, oseltamivir might reduce hospitalization.^{18,44} The results differed from our findings mainly because the previous meta-analyses only included studies published before 2014. Another more recent meta-analysis including 12 studies with 6295 outpatient patients reported that oseltamivir may not be associated with reduced risk of hospitalization and may be associated with increased nausea and vomiting.⁴⁵ Our findings on the effects of oseltamivir for non-severe influenza are consistent with results of this meta-analysis.⁴⁵ By increasing sample size, our review has added statistical power and improved the precision of estimates

and allowed the conclusion that oseltamivir does not result in an important reduction in symptom duration.

Our findings have significant implications for practice and research. Oseltamivir has been widely used for treatment of influenza. However, this review provided moderate to high certainty evidence that, compared to standard care or placebo, oseltamivir has little or no effect on mortality and admission to hospital both in low-risk and high-risk patients, probably has no important effect on time to alleviation of symptoms, and probably increases adverse events related to treatment. Therefore, our findings did not support the use of oseltamivir for treatment of non-severe influenza.

Baloxavir, relative to standard care, may reduce the risk of admission to hospital in high-risk patients, probably reduces time to alleviation of symptoms, and does not increase adverse events related to treatment. These findings support the use of baloxavir for treatment of high-risk non-severe influenza patients. However, drug resistance monitoring may be needed as baloxavir may increase emergence of drug resistance.

Our studies identify evidence gaps regarding antivirals for non-severe influenza. Future studies could focus on patient-important outcomes (e.g. admission to ICU, progression to mechanical ventilation, duration of hospitalization) and test important subgroup analyses such as the influenza virus type, age, patients at low risk or high risk, and time from onset of symptoms to treatment. Future antiviral trials of influenza should also pay greater attention to ensuring adequate allocation

concealment and blinding.

In patients with non-severe influenza, baloxavir may reduce the risk of admission to hospital for high-risk patients, probably reduces time to alleviation of symptoms, does not increase any adverse events and adverse events related to treatment, but may result in resistance in approximately 10% of those treated. Oseltamivir has little or no effect on mortality and admission to hospital, probably has no important effect on time to alleviation of symptoms, and probably increases adverse events related to treatment. All other antivirals are either probably not to be beneficial or have uncertain effects on patient-important outcomes.

Contributors

YG, GG, and QH conceived and designed the study. YG and QH designed and performed the search strategy. YG, YZ, ML, SL, and XC screened and selected the articles. YG, YZ, ML, SL, YC, XC, QZ, JX, YS, WZ, ZL, SH, and JH extracted the data and assessed the risk of bias. YG and QH analyzed the data. JT and GG supervised the data analyses. YG and QH rated the certainty of evidence. GG provided methodological advice on baseline risk selection and GRADE assessment. YG, YZ, GG, and QH interpreted the data. YG and QH drafted the manuscript. YG, GG, and QH revised the manuscript. All authors approved the final version of the manuscript. YG and QH accessed and verified the underlying data. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Data sharing statement

Data in this systematic review with meta-analysis are extracted from published studies available on the internet. All processed data are presented in this article and the appendix.

Declaration of interests

We declare no competing interests.

Acknowledgements

We thank Timothy M Uyeki (Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia; email: tmu0@cdc.gov) for help with identifying the drug resistance outcome, providing clinical advice, and interpreting the results. We thank members of the WHO for critical feedback on the review question, subgroup and outcome selection, and GRADE judgments: Janet Diaz (World Health Organization, Geneva, Switzerland; email: diazj@who.int); Steven Mcgloughlin (World Health Organization, Geneva, Switzerland; email: mcgloughlins@who.int); Jamie Rylance (World Health Organization, Geneva, Switzerland; email: rylancej@who.int). We thank Rachel Couban (librarian at McMaster University; email: rcouban@mcmaster.ca) for helping with developing the search strategy. We thank Ping Liu (The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; email: ping.liu.cqmu@outlook.com) for contributing to the literature screening.

References

1. Paules C, Subbarao K. Influenza. *Lancet* 2017; **390**(10095): 697-708.
2. Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza. *Lancet* 2022; **400**(10353): 693-706.
3. World Health Organization. WHO Influenza (seasonal) fact sheet. Geneva: World Health Organization; 2023. [https://www.who.int/news-room/fact-sheets/detail/influenza-\(seasonal\)](https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)). Accessed 6 February 2023.
4. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. *Lancet* 2018; **391**(10127): 1285-300.
5. Kumari R, Sharma SD, Kumar A, et al. Antiviral Approaches against Influenza Virus. *Clin Microbiol Rev* 2023: e0004022.
6. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. *Ann Intern Med* 2012; **156**(7): 512-24.
7. World Health Organization. Guidelines for the clinical management of severe illness from influenza virus infections. Geneva: World Health Organization; 2021. <https://www.who.int/publications/i/item/9789240040816>. Accessed 6 February 2023.
8. Liu JW, Lin SH, Wang LC, Chiu HY, Lee JA. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis. *JAMA Netw Open* 2021; **4**(8): e2119151.

9. Su HC, Feng IJ, Tang HJ, Shih MF, Hua YM. Comparative effectiveness of neuraminidase inhibitors in patients with influenza: A systematic review and network meta-analysis. *J Infect Chemother* 2022; **28**(2): 158-69.
10. Zhao Y, Huang G, He W, et al. Efficacy and safety of single-dose antiviral drugs for influenza treatment: A systematic review and network meta-analysis. *J Med Virol* 2022; **94**(7): 3270-302.
11. Butler CC, van der Velden AW, Bongard E, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. *Lancet (London, England)* 2020; **395**(10217): 42-52.
12. Hayden FG, Lenk RP, Stonis L, Oldham-Creamer C, Kang LL, Epstein C. Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. *The Journal of infectious diseases* 2022; **226**(10): 1790-9.
13. Bai X, Xi S, Chen G, et al. Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases. *BMC infectious diseases* 2023; **23**(1): 585.
14. Hsieh Y-H, Dugas AF, LoVecchio F, et al. Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: Results from a pilot randomized controlled study. *Influenza and other respiratory viruses* 2021; **15**(1): 121-31.
15. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care

- interventions: checklist and explanations. *Ann Intern Med* 2015; **162**(11): 777-84.
16. Brown SJ, Bakker CJ, Theis-Mahon NR. Retracted publications in pharmacy systematic reviews. *J Med Libr Assoc* 2022; **110**(1): 47-55.
17. Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. *The Lancet Infectious Diseases* 2020; **20**(10): 1204-14.
18. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. *Lancet* 2015; **385**(9979): 1729-37.
19. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Stat Med* 2006; **25**(20): 3443-57.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**(7109): 629-34.
21. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. *Arch Public Health* 2014; **72**(1): 39.
22. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC Med Res Methodol* 2014; **14**: 25.
23. Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. *BMC Med Res Methodol* 2021; **21**(1): 189.

24. Rucker G. Network meta-analysis, electrical networks and graph theory. *Res Synth Methods* 2012; **3**(4): 312-24.
25. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Synth Methods* 2012; **3**(2): 98-110.
26. König J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. *Stat Med* 2013; **32**(30): 5414-29.
27. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. *Stat Med* 2010; **29**(7-8): 932-44.
28. Friedrich JO, Adhikari NKJ, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. *Bmc Medical Research Methodology* 2007; **7**: 5.
29. McDonald SA, Teirlinck AC, Hooiveld M, et al. Inference of age-dependent case-fatality ratios for seasonal influenza virus subtypes A(H3N2) and A(H1N1)pdm09 and B lineages using data from the Netherlands. *Influenza and Other Respiratory Viruses* 2023; **17**(6): e13146.
30. Meier CR, Napalkov PN, Wegmüller Y, Jefferson T, Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. *Eur J Clin Microbiol* 2000; **19**(11): 834-42.
31. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. *Cochrane Handbook for Systematic Reviews of Interventions* version 6.3 (updated

February 2022). Cochrane Collaboration; 2022.

www.training.cochrane.org/handbook.

32. Schandelmaier S, Briel M, Varadhan R, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. *CMAJ* 2020; **192**(32): E901-e6.

33. Guyatt GH, Busse JW. Modification of cochrane tool to assess risk of bias in randomized trials. <https://www.evidencepartners.com/resources/methodological-resources/>. Accessed January 30, 2023.

34. Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014; **349**: g5630.

35. Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. *J Clin Epidemiol* 2018; **93**: 36-44.

36. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; **336**(7650): 924-6.

37. Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. *J Clin Epidemiol* 2021; **137**: 163-75.

38. Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. *J Clin Epidemiol* 2022; **150**: 216-24.

39. Hao Q, Gao Y, Zhao Y, et al. GRADE concept 6: a novel application of external indirect evidence into GRADE ratings of evidence certainty in network meta-analysis. *J Clin Epidemiol* 2023; **163**: 95-101.
40. Carrasco-Labra A, Brignardello-Petersen R, Santesso N, et al. Improving GRADE evidence tables part 1: a randomized trial shows improved understanding of content in summary of findings tables with a new format. *J Clin Epidemiol* 2016; **74**: 7-18.
41. Santesso N, Glenton C, Dahm P, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol* 2020; **119**: 126-35.
42. Taieb V, Ikeoka H, Ma FF, et al. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. *Curr Med Res Opin* 2019; **35**(8): 1355-64.
43. Taieb V, Ikeoka H, Wojciechowski P, et al. Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis. *Curr Med Res Opin* 2021; **37**(2): 225-44.
44. Shim SJ, Chan M, Owens L, Jaffe A, Prentice B, Homaira N. Rate of use and effectiveness of oseltamivir in the treatment of influenza illness in high-risk populations: A systematic review and meta-analysis. *Health Sci Rep* 2021; **4**(1): e241.
45. Hanula R, Bortolussi-Courval E, Mendel A, Ward BJ, Lee TC, McDonald EG. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-Analysis. *JAMA Intern Med* 2024; **184**(1):

18-27.

Figure legends

Figure 1. Study selection

Figure 2. Network plot for mortality (A) time to alleviation of symptoms (B)

Footnotes: The size of the circle represents the number of participants. The connecting lines represent direct comparisons. The width of the line represents the number of studies.

Figure 3. Summary of effects of antivirals versus standard care or placebo, presented as absolute effects with 95% confidence intervals (CIs)

11845 Records identified through databases searching

33 Potentially eligible studies identified from relevant reviews

8944 Records after duplicates removed


8485 Records excluded for not being relevant

459 Full-text articles assessed for eligibility

372 Full-text articles excluded

- 117** Not randomized controlled trials
- 66** Wrong intervention
- 29** Registration records of published trials
- 18** Registration records without results
- 36** Inappropriate population
- 14** Abstracts of published trials
- 36** No outcome of interest
- 10** Wrong comparator
- 4** Secondary data analysis
- 3** Protocols
- 28** Prevention study reports
- 11** Severe influenza

87 Reports reported **73** unique randomized controlled trials included






Figure 3: Summary of effects of antivirals versus standard care or placebo, presented as absolute effects with 95% confidence intervals (CIs)

Antivirals	Mortality		Admission to hospital		Admission to ICU	Any adverse events	Adverse events related to treatments	Serious adverse events	Time to alleviation of symptoms	Duration of hospitalization
	Low risk patients	High risk patients	Low risk patients	High risk patients						
Baseline risk	0.2 per 1000	2 per 1000	3 per 1000	21 per 1000	2 per 1000	346 per 1000	122 per 1000	5 per 1000	4.92 days	5.52 days
Baloxavir	-0.03 (-0.17 to 0.76)	-0.34 (-1.72 to 7.64)	-2 (-3 to 1)	-16 (-20 to 4)	No data	-52 (-87 to -17)	-32 (-52 to -6)	1 (-4 to 5)	-1.02 (-1.41 to -0.63)	No data
Favipiravir	-0.09 (-0.19 to 1.63)	-0.86 (-1.92 to 16.30)	-1 (-3 to 24)	-9 (-20 to 171)	No data	-14 (-62 to 45)	-13 (-41 to 24)	-2 (-7 to 4)	-0.46 (-0.96 to 0.03)	No data
Laninamivir	-0.10 (-0.20 to 4.79)	-1.00 (-1.98 to 47.92)	0 (-3 to 163)	2 (-21 to 979)	No data	-38 (-332 to 654)	No data	-4 (-11 to 3)	-0.57 (-1.01 to -0.14)	No data
Oseltamivir	-0.03 (-0.13 to 0.21)	-0.32 (-1.32 to 2.14)	-1 (-1 to 1)	-4 (-10 to 4)	-2 (-7 to 3)	-10 (-28 to 10)	28 (12 to 48)	0 (-3 to 2)	-0.75 (-0.93 to -0.57)	-0.35 (-3.19 to 2.49)
Peramivir	-0.12 (-0.19 to 0.61)	-1.22 (-1.92 to 6.08)	No data	No data	19 (-17 to 55)	-14 (-38 to 17)	-1 (-32 to 39)	0 (-7 to 6)	-0.95 (-1.28 to -0.62)	-1.04 (-3.90 to 1.82)
Umifenovir	-0.03 (-0.20 to 9.26)	-0.30 (-1.96 to 92.62)	-2 (-3 to 17)	-15 (-21 to 120)	No data	-114 (-253 to 235)	-52 (-94 to 45)	No data	-1.10 (-1.57 to -0.63)	No data
Zanamivir	-0.02 (-0.13 to 0.26)	-0.24 (-1.32 to 2.56)	1 (-1 to 2)	4 (-4 to 15)	No data	-28 (-48 to -7)	6 (-12 to 26)	2 (-1 to 6)	-0.68 (-0.93 to -0.43)	-1.10 (-2.30 to 0.10)
Amantadine	No data	No data	No data	No data	No data	No data	No data	No data	-0.78 (-1.30 to -0.26)	No data

High certainty Moderate certainty Low certainty Very low certainty

Numbers in the colored cell are the estimated risk differences (95% CI) per 1000 patients or mean difference (95% CI) in days when compared with standard care or placebo.

Table 1. Summary of findings table for baloxavir versus standard care or placebo

Outcome	Study results and measurements	Absolute effect estimates		Certainty of the Evidence (Quality of evidence)	Summary
		Standard care/placebo	Baloxavir		
Mortality (Low-risk)	Relative risk: 0.83 (CI 95% 0.14 - 4.82) Based on data from 2144 participants in 2 studies	0.20 per 1000	0.17 per 1000	High	Baloxavir has little or no effect on mortality.
		Difference: 0.03 fewer per 1000 (CI 95% 0.17 fewer - 0.76 more)			
Mortality (High-risk)	Relative risk: 0.83 (CI 95% 0.14 - 4.82) Based on data from 2144 participants in 2 studies	2.0 per 1000	1.66 per 1000	High	Baloxavir has little or no effect on mortality.
		Difference: 0.34 fewer per 1000 (CI 95% 1.72 fewer - 7.64 more)			
Admission to hospital (Low-risk)	Relative risk: 0.24 (CI 95% 0.05 - 1.19) Based on data from 1461 participants in 2 studies	3 per 1000	1 per 1000	High	Baloxavir has little or no effect on admission to hospital.
		Difference: 2 fewer per 1000 (CI 95% 3 fewer - 1 more)			
Admission to hospital (High-risk)	Relative risk: 0.24 (CI 95% 0.05 - 1.19) Based on data from 1461 participants in 2 studies	21 per 1000	5 per 1000	Low Due to very serious imprecision	Baloxavir may reduce the risk of admission to hospital.
		Difference: 16 fewer per 1000 (CI 95% 20 fewer - 4 more)			
Adverse events related to treatments	Relative risk: 0.74 (CI 95% 0.57 - 0.95) Based on data from 2776 participants in 3 studies	122 per 1000	90 per 1000	High	Baloxavir does not increase adverse events related to treatments.
		Difference: 32 fewer per 1000 (CI 95% 52 fewer - 6 fewer)			
Serious adverse events	Risk difference: 0.001 (CI 95% -0.004 – 0.005) Based on data from 2776 participants in 3 studies	5 per 1000	6 per 1000	Moderate Due to serious imprecision	Baloxavir probably has little or no effect on serious adverse events.
		Difference: 1 more per 1000 (CI 95% 4 fewer - 5 more)			
Time to alleviation of symptoms	Measured by: day Lower better Based on data from 1855 participants in 3 studies	4.92 Mean	3.90 Mean	Moderate Due to serious imprecision	Baloxavir probably reduces time to alleviation of symptoms.
		Difference: MD 1.02 lower (CI 95% 1.41 lower - 0.63 lower)			

Table 2. Summary of findings table for oseltamivir versus standard care or placebo

Outcome	Study results and measurements	Absolute effect estimates		Certainty of the Evidence (Quality of evidence)	Summary
		Standard care/placebo	Oseltamivir		
Mortality (Low-risk)	Relative risk: 0.84 (CI 95% 0.34 - 2.07) Based on data from 12008 participants in 17 studies	0.20 per 1000	0.17 per 1000	High	Oseltamivir has little or no effect on mortality.
		Difference: 0.03 fewer per 1000 (CI 95% 0.13 fewer - 0.21 more)			
Mortality (High-risk)	Relative risk: 0.84 (CI 95% 0.34 - 2.07) Based on data from 12008 participants in 17 studies	2.0 per 1000	1.68 per 1000	High	Oseltamivir has little or no effect on mortality.
		Difference: 0.32 fewer per 1000 (CI 95% 1.32 fewer - 2.14 more)			
Admission to hospital (Low-risk)	Relative risk: 0.8 (CI 95% 0.54 - 1.18) Based on data from 12589 participants in 20 studies	3 per 1000	2 per 1000	High	Oseltamivir has little or no effect on admission to hospital.
		Difference: 1 fewer per 1000 (CI 95% 1 fewer - 1 more)			
Admission to hospital (High-risk)	Relative risk: 0.80 (CI 95% 0.54 - 1.18) Based on data from 12589 participants in 20 studies	21 per 1000	17 per 1000	High	Oseltamivir has little or no effect on admission to hospital.
		Difference: 4 fewer per 1000 (CI 95% 10 fewer - 4 more)			
Adverse events related to treatments	Relative risk: 1.23 (CI 95% 1.1 - 1.39) Based on data from 6782 participants in 12 studies	122 per 1000	150 per 1000	Moderate Due to serious risk of bias	Oseltamivir probably increases adverse events related to treatments.
		Difference: 28 more per 1000 (CI 95% 12 more - 48 more)			
Serious adverse events	Risk difference: 0.0 (CI 95% -0.003 - 0.002) Based on data from 14718 participants in 22 studies	5 per 1000	5 per 1000	Moderate Due to serious risk of bias	Oseltamivir probably has little or no effect on serious adverse events.
		Difference: 0 fewer per 1000 (CI 95% 3 fewer - 2 more)			
Time to alleviation of symptoms	Measured by: day Lower better Based on data from 9078 participants in 22 studies	4.92 Mean	4.17 Mean	Moderate Due to serious risk of bias	Oseltamivir probably has no important effect on time to alleviation of symptoms.
		Difference: MD 0.75 lower (CI 95% 0.93 lower - 0.57 lower)			